Alzheimer's disease & dementia

Biogen calls criticism of Alzheimer's drug 'misinformation'

Biogen Inc. fought back against criticism of the unusual circumstances that led to the U.S. approval of its Alzheimer's drug Aduhelm, saying in an open letter it has been the subject of "extensive misinformation and misunderstanding."

Medical economics

Patient engagement may not drive return to in-person visits

(HealthDay)—Patient engagement strategies appear to yield few return visits upon reopening during COVID-19 for patients who cancelled in-person care during the earlier portion of the pandemic, according to a research letter ...

page 1 from 12